Praxis Precision Medicines (NASDAQ: PRAX) is lighting up screens this morning — the stock is soaring over 150% in pre-market trading after the Boston-based biotech announced game-changing Phase 3 results for its essential tremor (ET) treatment, ulixacaltamide HCl.
📈 Why Traders Are Paying Attention
Essential tremor is a neurological condition that causes uncontrollable shaking and affects millions of people — yet treatment options have been extremely limited. Today’s news puts Praxis at the center of a multi-billion-dollar marketand is one of the most bullish catalysts traders could ask for: a successful pivotal trial.
✅ Phase 3 Data Hits All the Right Notes
Praxis released positive topline results from two pivotal Phase 3 studies in its Essential3 program:
- Study 1 (Parallel-Group Trial): Patients treated with ulixacaltamide showed a statistically significant 4.3-point mean improvement from baseline in the Modified Activities of Daily Living 11 score at Week 8 — meeting the primary endpoint. All key secondary endpoints were also statistically significant.
- Study 2 (Randomized Withdrawal Trial): The drug again met its primary endpoint — 55% of patients maintained their treatment benefit versus 33% on placebo. Ulixacaltamide-treated patients also showed superior disease improvement throughout the withdrawal phase.
Dr. Salima Brillman, co-lead investigator, summed it up best:
“For the first time we have a medication designed specifically for our ET patients. Ulixacaltamide represents more than data on a chart — it’s a real opportunity to help people regain their independence.”
🩺 Safety and Next Steps
The drug was well tolerated, with no drug-related serious adverse events. Most common side effects were mild and included constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia, and insomnia.
Praxis has already submitted a pre-NDA meeting request with the FDA and plans to file a New Drug Application by early 2026, pending agency feedback.
Importantly, patients in these trials had been living with essential tremor for an average of 30 years — highlighting the massive unmet medical need and the potential scale of ulixacaltamide’s impact.
📊 Bottom Line for Traders
This isn’t just another biotech press release — Praxis now has pivotal-level data in hand for a first-in-class treatmentin a high-need condition. That explains the triple-digit pre-market surge and growing attention from retail and institutional traders alike.
If the FDA review stays on track, PRAX could be on the fast track to commercialization — and today’s breakout could be just the start of a bigger story.
